Assessing favipiravir impact on SARS-CoV-2 transmission within households: Insights from a multi-center study (FaviPrev)

Taweegrit Siripongboonsitti, Marisa Muadchimkaew, Kriangkrai Tawinprai, Ornisa Issaranon, Wichuda Meepholkij, Pureepat Arttawejkul, Apiradee Vararungzarit, Onwalee Dhissayakamol, Wilaiporn Preeyachit, Kamonwan Soonklang, Nithi Mahanonda · 2024

Read Assessing favipiravir impact on SARS-CoV-2 transmission within households: Insights from a multi-center study (FaviPrev) by Taweegrit Siripongboonsitti, Marisa Muadchimkaew, Kriangkrai Tawinprai, Ornisa Issaranon, Wichuda Meepholkij, Pureepat Arttawejkul, Apiradee Vararungzarit, Onwalee Dhissayakamol, Wilaiporn Preeyachit, Kamonwan Soonklang, Nithi Mahanonda (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11721425.txt.

Description

Taweegrit Siripongboonsitti and ten co-authors asked whether treating a COVID-19 patient with the antiviral favipiravir protects people they live with. In a multicenter Thai study from 2021 to 2022, nearly nine hundred mildly ill index patients received the drug, against eighty-four on standard care; their households were followed for new infections. About eighteen hundred contacts of treated patients were compared with one hundred seventy contacts of untreated ones.

The secondary attack rate was fifty-eight percent in favipiravir households against about seventy-two percent without it, halving the odds of transmission. The protection showed most clearly when the index patient was unvaccinated, clearly symptomatic, living in crowded housing such as dormitories or flats, or not masking at home. The authors say an antiviral given to the sick person may double as a shield for the household. They call for the same test of other anti-COVID drugs.

Catalog record

CREATORTaweegrit Siripongboonsitti, Marisa Muadchimkaew, Kriangkrai Tawinprai, Ornisa Issaranon, Wichuda Meepholkij, Pureepat Arttawejkul, Apiradee Vararungzarit, Onwalee Dhissayakamol, Wilaiporn Preeyachit, Kamonwan Soonklang, Nithi Mahanonda
YEAR2024
COLLECTIONPAPERS
FORMATTXT
FILE SIZE60 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11721425

Browse the full library · About the Tower of Babel